IL276888A - Pharmaceutical composition comprising timolol - Google Patents
Pharmaceutical composition comprising timololInfo
- Publication number
- IL276888A IL276888A IL276888A IL27688820A IL276888A IL 276888 A IL276888 A IL 276888A IL 276888 A IL276888 A IL 276888A IL 27688820 A IL27688820 A IL 27688820A IL 276888 A IL276888 A IL 276888A
- Authority
- IL
- Israel
- Prior art keywords
- timolol
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229960004605 timolol Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18164563 | 2018-03-28 | ||
EP18185436 | 2018-07-25 | ||
PCT/EP2019/057429 WO2019185543A1 (en) | 2018-03-28 | 2019-03-25 | Pharmaceutical composition comprising timolol |
Publications (2)
Publication Number | Publication Date |
---|---|
IL276888A true IL276888A (en) | 2020-10-29 |
IL276888B1 IL276888B1 (en) | 2024-08-01 |
Family
ID=65818028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL276888A IL276888B1 (en) | 2018-03-28 | 2019-03-25 | Pharmaceutical composition comprising timolol |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210121471A1 (en) |
EP (1) | EP3773469A1 (en) |
JP (1) | JP7496778B2 (en) |
KR (1) | KR20200136403A (en) |
CN (1) | CN111867560B (en) |
AU (1) | AU2019246035B2 (en) |
BR (1) | BR112020017841A2 (en) |
CA (1) | CA3091313A1 (en) |
IL (1) | IL276888B1 (en) |
MX (1) | MX2020010078A (en) |
SG (1) | SG11202007860XA (en) |
WO (1) | WO2019185543A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018054932A1 (en) | 2016-09-22 | 2018-03-29 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
CA3036306C (en) | 2016-09-23 | 2024-05-14 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
SG11202002640YA (en) | 2017-09-27 | 2020-04-29 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19536504C2 (en) * | 1995-09-29 | 1999-09-23 | H Meinert | Use of fluorinated alkanes |
US6335335B2 (en) | 1997-11-05 | 2002-01-01 | Senju Pharmaceutical Co., Ltd. | Prolonged-action eye drop |
TWI298257B (en) * | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
US7030149B2 (en) * | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
CA2481394A1 (en) * | 2002-05-24 | 2003-12-04 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Drop-forming ophthalmic gel preparation comprising diclofenamide and timolol |
US20070238732A1 (en) * | 2006-04-10 | 2007-10-11 | Allergan, Inc. | Brimonidine and timolol compositions |
EP2178502A2 (en) * | 2007-06-21 | 2010-04-28 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
EP2444063A1 (en) * | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) * | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
JP2012250951A (en) * | 2011-06-06 | 2012-12-20 | Santen Pharmaceut Co Ltd | COMBINATION AGENT OF ADENOSINE DERIVATIVE, PROSTAGLANDIN AND β-RECEPTOR BLOCKER |
US11285163B2 (en) * | 2014-10-20 | 2022-03-29 | Sentiss Pharma Private Limited | Ophthalmic solution |
WO2016082644A1 (en) * | 2014-11-26 | 2016-06-02 | The University Of Hong Kong | A semifluorinated alkane based cleaner for removing emulsified droplets in the eye to reduce the complications associated with the emulsification of silicone oil |
KR102257916B1 (en) * | 2016-06-23 | 2021-05-28 | 노바리크 게엠베하 | Kit including drop dispenser |
-
2019
- 2019-03-25 AU AU2019246035A patent/AU2019246035B2/en active Active
- 2019-03-25 WO PCT/EP2019/057429 patent/WO2019185543A1/en unknown
- 2019-03-25 US US17/041,758 patent/US20210121471A1/en active Pending
- 2019-03-25 CN CN201980018538.6A patent/CN111867560B/en active Active
- 2019-03-25 EP EP19711929.0A patent/EP3773469A1/en active Pending
- 2019-03-25 KR KR1020207027430A patent/KR20200136403A/en not_active Application Discontinuation
- 2019-03-25 BR BR112020017841-1A patent/BR112020017841A2/en unknown
- 2019-03-25 SG SG11202007860XA patent/SG11202007860XA/en unknown
- 2019-03-25 IL IL276888A patent/IL276888B1/en unknown
- 2019-03-25 MX MX2020010078A patent/MX2020010078A/en unknown
- 2019-03-25 JP JP2020549581A patent/JP7496778B2/en active Active
- 2019-03-25 CA CA3091313A patent/CA3091313A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN111867560B (en) | 2024-08-13 |
JP7496778B2 (en) | 2024-06-07 |
BR112020017841A2 (en) | 2020-12-22 |
IL276888B1 (en) | 2024-08-01 |
US20210121471A1 (en) | 2021-04-29 |
AU2019246035A1 (en) | 2020-09-10 |
MX2020010078A (en) | 2021-02-26 |
AU2019246035B2 (en) | 2024-07-18 |
WO2019185543A1 (en) | 2019-10-03 |
CA3091313A1 (en) | 2019-10-03 |
CN111867560A (en) | 2020-10-30 |
EP3773469A1 (en) | 2021-02-17 |
SG11202007860XA (en) | 2020-09-29 |
KR20200136403A (en) | 2020-12-07 |
JP2021518352A (en) | 2021-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279442A (en) | Pharmaceutical compositions comprising meloxicam | |
GB201807942D0 (en) | Pharmaceutical formulation | |
IL269061A (en) | Pharmaceutical composition comprising selexipag | |
PL3452075T3 (en) | Ophthalmic pharmaceutical composition | |
IL276888A (en) | Pharmaceutical composition comprising timolol | |
GB201911517D0 (en) | Pharmaceutical composition | |
GB201804548D0 (en) | Pharmaceutical compositions | |
EP3851121A4 (en) | Human anti-il-33 monoclonal-antibody-containing pharmaceutical composition | |
IL290894A (en) | Pharmaceutical formulation | |
GB201807053D0 (en) | Pharmaceutical composition | |
GB201808571D0 (en) | Pharmaceutical compositions | |
SG11202103374TA (en) | Pharmaceutical composition | |
GB201808567D0 (en) | Pharmaceutical compositions | |
EP3603641A4 (en) | Pharmaceutical composition containing dusp1 inhibitor | |
IL279707A (en) | Pharmaceutical composition comprising polypeptide | |
SG11202110315SA (en) | Pharmaceutical composition | |
SI3908321T1 (en) | Pharmaceutical composition | |
IL280989A (en) | Pharmaceutical compositions comprising integration-promoting peptides | |
GB201906473D0 (en) | Pharmaceutical formulation | |
EP3664798A4 (en) | Pharmaceutical composition comprising eliglustat | |
ZA202006541B (en) | Pharmaceutical composition comprising brexpiprazole | |
IL285728A (en) | Pharmaceutical composition | |
GB201912686D0 (en) | Pharmaceutical composition | |
GB201908003D0 (en) | Pharmaceutical composition | |
GB201820689D0 (en) | Pharmaceutical composition |